Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome

Chang,Ming‑Hui; Chou,Jen‑Wei; Chen,Shan‑Ming; Tsai,Ming‑Chang; Sun,Yu‑Shu; Lin,Chun‑Che; Lin,Ching‑Pin

doi:10.3892/mmr.2014.2180

July-2014 Volume 10 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2014 Volume 10 Issue 1

Full Size Image

Article

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome

Authors:
- Ming‑Hui Chang
- Jen‑Wei Chou
- Shan‑Ming Chen
- Ming‑Chang Tsai
- Yu‑Shu Sun
- Chun‑Che Lin
- Ching‑Pin Lin
View Affiliations / Copyright

Affiliations: Division of Hepatology and Gastroenterology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C., Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C., Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C., National Defense Medical Center, Taipei, Taiwan, R.O.C.
Pages: 522-526
|
Published online on: April 24, 2014

https://doi.org/10.3892/mmr.2014.2180
Expand metrics +

Abstract

The present study aimed to investigate faecal calprotectin as a diagnostic marker to differentiate between patients with inflammatory bowel disease (IBD) and those with irritable bowel syndrome (IBS). A total of 20 healthy control subjects, 26 patients with IBS and 58 patients with IBD, including 22 with ulcerative colitis (UC) and 36 with Crohn's disease (CD), were recruited for the present study. Calprotectin was analysed in stool samples, and C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) were assessed in blood samples. CRP and calprotectin levels, and the ESR were observed to be significantly higher in patients with CD and UC compared with those of the healthy control subjects (P<0.0001). Furthermore, in patients with IBD and IBS, significant increases in faecal calprotectin and CRP levels were observed (694.8±685.0 µg/g in IBD vs. 85.8±136.1 µg/g in IBS and 0.851±1.200 mg/dl in IBD vs. 0.16±0.23 mg/dl in IBS, respectively; P<0.0001). Area under the receiver operating characteristic curve analysis revealed that, in patients with IBD, the levels of faecal calprotectin [0.931±0.029; 95% confidence interval (CI), 0.874‑0.987] were significantly higher than that of CRP (0.865±0.041; 95% CI, 0.785‑0.946) and the ESR (0.869±0.042; 95% CI, 0.786‑0.952). These findings indicate that faecal calprotectin may represent a novel biomarker for diagnosing IBD and may be effective in distinguishing between IBD and IBS.

View Figures

View References

1	Walkiewicz D, Werlin SL, Fish D, et al: Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 14:669–673. 2008. View Article : Google Scholar : PubMed/NCBI
2	Paduchova Z and Durackova Z: Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy. 110:598–602. 2009.PubMed/NCBI
3	Jahnsen J, Røseth AG and Aadland E: Measurement of calprotectin in faeces. Tidsskr Nor Laegeforen. 129:743–745. 2009.(In Norwegian).
4	Costa F, Mumolo MG, Bellini M, et al: Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 35:642–647. 2003. View Article : Google Scholar : PubMed/NCBI
5	Tibble JA, Sigthorsson G, Bridger S, et al: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 119:15–22. 2000. View Article : Google Scholar : PubMed/NCBI
6	Önal IK, Beyazit Y, Şener B, et al: The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. Turk J Gastroenterol. 23:509–514. 2012.PubMed/NCBI
7	Røseth AG, Aadland E and Grzyb K: Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 39:1017–1020. 2004.PubMed/NCBI
8	Sherwood RA: Faecal markers of gastrointestinal inflammation. J Clin Pathol. 65:981–985. 2012. View Article : Google Scholar : PubMed/NCBI
9	Malchow H, Ewe K, Brandes JW, et al: European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 86:249–266. 1984.
10	Bitton A, Peppercorn MA, Antonioli DA, et al: Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 120:13–20. 2001. View Article : Google Scholar : PubMed/NCBI
11	Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 130:1377–1390. 2006. View Article : Google Scholar : PubMed/NCBI
12	Henderson AR: Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem. 30:521–539. 1993. View Article : Google Scholar : PubMed/NCBI
13	Costa F, Mumolo MG, Ceccarelli L, et al: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 54:364–368. 2005.PubMed/NCBI
14	D’Incà R, Dal Pont E, Di Leo V, et al: Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 103:2007–2014. 2008.PubMed/NCBI
15	Hanai H, Takeuchi K, Iida T, et al: Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci. 49:1438–1443. 2004. View Article : Google Scholar
16	Gisbert JP, Bermejo F, Pérez-Calle JL, et al: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 15:1190–1198. 2009. View Article : Google Scholar : PubMed/NCBI
17	Gundling F, Schmidtler F, Hapfelmeier A, et al: Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int. 31:1406–1415. 2011. View Article : Google Scholar : PubMed/NCBI
18	van Rheenen PF, Van de Vijver E and Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 341:c33692010.PubMed/NCBI
19	Carroccio A, Iacono G, Cottone M, et al: Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 49:861–867. 2003. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles